May 3rd 2024
Data also highlight a favorable overall survival trend with the acalabrutinib regimen in the phase 3 ECHO trial.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Many Great Treatments Available for MCL But Questions About Sequencing Remain, Expert Says
December 18th 2022In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.
Real-World Quality-of-Life Outcomes of Axi-Cel Treatment in Lymphoma Subtypes Align With Trial Data
December 14th 2022Real-world data associate axicabtagene ciloleucel with temporarily worse quality of life in patients with diffuse large B cell lymphoma, transformed follicular lymphoma, or follicular lymphoma, which improves within 1-year post-infusion.
Addition of Ibrutinib to CRT/ASCT Appears to Improve Outcomes for MCL
December 13th 2022Treatment with induction and maintenance ibrutinib combined with chemoimmunotherapy and autologous stem cell transplant resulted in statistically significantly improved outcomes in a younger population with mantle cell lymphoma.
Rapcabtagene Autoleucel Shows Promise in Relapsed/Refractory DLBCL
December 11th 2022Rapcabtagene autoleucel, a novel CAR T-cell therapy, was promisingly effective and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma, according to findings from a phase 1 dose-escalation study.
Ibrutinib-Venetoclax Combo Appears Effective in Previously Untreated Waldenström Macroglobulinemia
December 11th 2022Patients with previously untreated Waldenström Macroglobulinemia—a rare form of blood cancer—derived fast and durable responses after receiving treatment with ibrutinib plus venetoclax, according to findings from a prospective phase 2 trial presented at 2022 ASH Annual Meeting.
Lenalidomide Plus Rituximab Improved PFS in 5-Year Follow-Up for R/R Indolent Non-Hodgkin Lymphoma
December 10th 2022The 5-year follow-up of the phase 3 AUGMENT trial produced enhanced progression-free survival when lenalidomide plus rituximab was used to treat patients with relapsed/refractory indolent non-Hodgkin lymphoma.
FDA Accepts BLA for Denileukin Diftitox in Cutaneous Persistent/Recurrent T-Cell Lymphoma
December 4th 2022The FDA’s acceptance of the biologics license application for denileukin diftitox for the treatment of patients with cutaneous persistent or recurrent T-cell lymphoma was supported by data from a pivotal phase 3 trial.
Zandelisib Demonstrates Promising Responses in Relapsed/Refractory Non-Hodgkin Lymphoma
November 21st 2022Topline results from the phase 2 MIRAGE study indicated that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma receiving zandelisib experienced an objective response rate of 75.4%.
Real-World Study Highlights Poor OS in Relapsed/Refractory MCL Following BTK Inhibitor Failure
November 7th 2022Real-world results from the retrospective SCHOLAR-2 study provided a benchmark for survival in patients with relapsed or recurrent refractory mantle cell lymphoma who received salvage therapy following failure of initial Bruton tyrosine kinase inhibitor therapy.
Atezolizumab With R-CHOP Shows Long-Lasting Activity in Previously Untreated DLBCL
November 4th 2022Atezolizumab plus R-CHOP appeared to yield durable clinical benefit and a safety profile consistent with known toxicities in patients with previously untreated DLBCL, according to data from a phase 1b/2 trial.